PTC Therapeutics Up 11%

Shares of biopharmaceutical company PTC Therapeutics, Inc. (PTCT) are rising 11 percent on Tuesday's trading, continuing their upward trend since the past few days.

Tuesday's rise can be attributed to news that the company would be reviewing the topline results from its study 041 of Translarna or ataluren in patients with nonsense mutation Duchenne muscular dystrophy, which is a rare and fatal genetic disorder.

Currently at $32.53, the stock has traded between $25.01 and $45.80 during the past 52 weeks.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.
Follow RTT